NASD · Healthcare · Biotechnology · Canada
Xenon Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing therapeutics for neurological and psychiatric disorders. The company is advancing azetukalner, a potassium channel opener being studied in trials for epilepsy, major depressive disorder, and bipolar depression. Its early-stage pipeline includes additional potassium channel and sodium channel modulators for conditions such as pain.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Xenon Pharmaceuticals Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on XENE yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.